Key Financials Snapshot

TTM · Consolidated · ₹ in Cr
Market Cap
₹1760 Cr.
Stock P/E
-55.8
P/B
1.8
Current Price
₹91.6
Book Value
₹ 51.6
Face Value
1
52W High
₹204.4
52W Low
₹ 88.3
Dividend Yield
0%

Camlin Fine Sciences Overview

Business

Camlin Fine Sciences Ltd. (CFSL) is a leading global manufacturer and supplier of specialty chemicals and ingredients, primarily catering to the food, feed, personal care, fragrance, and pharmaceutical industries. The company's core business involves the production of a range of products including antioxidants (such as TBHQ, BHA), aroma chemicals (like Vanillin, Ethyl Vanillin), performance chemicals, and nutrition ingredients. CFSL operates on a business-to-business (B2B) model, selling its manufactured products to other companies for use in their end products. The company generates revenue by leveraging its expertise in chemical synthesis, backward integration for key raw materials, and a global distribution network.

Revenue Mix

Camlin Fine Sciences operates primarily in the specialty chemicals domain, which can be broadly segmented by product type and end-use application. While specific revenue contributions by segment are not publicly detailed consistently, the key product categories include:

Antioxidants: A significant portion of their business, including products like Tertiary Butylhydroquinone (TBHQ), Butylated Hydroxyanisole (BHA), and Ascorbyl Palmitate, used in food, feed, and industrial applications for shelf-life extension and stability.

Aroma Chemicals: This segment includes Vanillin and Ethyl Vanillin, which are key flavor and fragrance ingredients used in food & beverages, personal care, and pharmaceutical industries.

Performance Chemicals & Nutrition Ingredients: This segment encompasses a range of other specialty chemicals and nutritional solutions.

The company is known to be a global leader in certain antioxidant chemistries and a prominent player in vanillin production.

Industry

Camlin Fine Sciences operates in the global specialty chemicals industry, which is characterized by diverse applications, demand from multiple end-user sectors, and a focus on R&D and process innovation. The food and feed additives market, in particular, is driven by population growth, changing dietary habits, and food preservation needs. CFSL is well-positioned as a leading global producer of specific antioxidants like TBHQ and BHA, and a significant manufacturer of vanillin/ethyl vanillin. It competes with both large multinational chemical corporations and other niche specialty chemical players globally. The company differentiates itself through backward integration for key raw materials (e.g., catechol for vanillin, hydroquinone for TBHQ) and a focus on product quality and certifications required by global food and feed industries.

MOAT

Backward Integration: CFSL has invested significantly in backward integration for key raw materials like Catechol and Hydroquinone. This provides cost advantages, ensures supply chain stability, reduces reliance on external suppliers, and offers better control over product quality, acting as a significant barrier to entry for new players.

Process Know-how & R&D: Expertise in complex chemical synthesis and continuous investment in R&D allow the company to develop efficient manufacturing processes and innovate new products, enhancing product differentiation and cost-effectiveness.

Customer Stickiness & Regulatory Hurdles: In B2B specialty chemicals, especially for food and feed applications, switching costs can be high due to rigorous qualification processes, lengthy approval cycles, and the need for consistent quality and regulatory compliance from suppliers. CFSL's established reputation and certifications create customer loyalty.

Scale of Operations: For its core products like TBHQ and Vanillin, CFSL operates on a significant scale, allowing for economies of scale in manufacturing and procurement.

Growth Drivers

Increasing Demand for Processed Food & Feed: Global population growth, urbanization, and changing lifestyles are driving the demand for processed foods, convenience foods, and feed additives, which in turn boosts the need for antioxidants and other specialty ingredients.

Expansion in Aroma Chemicals: Growth in the food & beverage, personal care, and fragrance industries globally supports the demand for aroma chemicals like Vanillin and Ethyl Vanillin.

Capacity Expansions & Debottlenecking: The company's strategic investments in expanding existing capacities and setting up new facilities are expected to cater to growing demand and increase market share.

Diversification into Value-Added Products: Focus on developing and commercializing new, high-margin, value-added products and expanding into related specialty chemical segments can drive future growth.

Global Market Penetration: Enhancing its presence in key international markets through its global distribution network.

Risks

Raw Material Price Volatility: The company's profitability is susceptible to fluctuations in the prices of key raw materials, many of which are crude oil derivatives or other commodity chemicals.

Intense Competition: The specialty chemicals industry is competitive, with both large global players and smaller regional manufacturers. This can lead to pricing pressures and impact market share.

Regulatory Changes: The food, feed, and pharmaceutical industries are highly regulated. Changes in food safety standards, permissible additive levels, or environmental regulations in key markets can impact product demand or increase operational costs.

Foreign Exchange Fluctuations: A significant portion of CFSL's revenues and costs are denominated in foreign currencies, making it exposed to currency exchange rate volatility.

Environmental Regulations: Stricter environmental compliance norms and increasing scrutiny of chemical manufacturing processes can lead to higher capital expenditure and operating costs.

Geopolitical Risks: Global trade tensions, supply chain disruptions, or economic slowdowns in key markets can negatively impact demand and profitability.

Management & Ownership

Camlin Fine Sciences is promoted by the Daftary family, who have a long history in the chemicals industry, originally associated with Camlin Ltd. The management team typically comprises experienced professionals with a strong understanding of the specialty chemicals domain and global markets. The promoter group generally holds a significant stake in the company, which is common in Indian businesses, indicating alignment of interests between promoters and shareholders.

Outlook

Camlin Fine Sciences is well-positioned in the growing global specialty chemicals market, particularly in food and feed additives and aroma chemicals. Its strong backward integration and focus on R&D provide a competitive edge in terms of cost efficiency and quality control. The company's ongoing capacity expansions and efforts to diversify its product portfolio into higher-value segments are positive indicators for future growth. However, the business remains susceptible to volatility in raw material prices, intense competition, and evolving regulatory landscapes, which can impact profitability. A sustained focus on operational efficiency, product innovation, and strategic market penetration will be crucial for navigating these challenges and realizing its growth potential.

Camlin Fine Sciences Share Price

Live · BSE / NSE · Inception: 1993
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Consolidated · annual

Camlin Fine Sciences Quarterly Results

#(Fig in Cr.) Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 377 381 417 431 432 408 460 457 425 520
Other Income 6 2 11 1 11 7 5 3 24 1
Total Income 382 383 429 432 443 414 464 460 449 521
Total Expenditure 345 352 366 373 370 387 426 435 404 511
Operating Profit 37 31 63 59 73 27 38 25 45 11
Interest 16 23 26 34 15 15 19 18 23 14
Depreciation 13 15 17 14 17 16 19 17 21 19
Exceptional Income / Expenses 0 0 -4 0 -6 0 0 -18 -8 -11
Profit Before Tax 8 -7 16 11 36 -4 0 -28 -7 -34
Provision for Tax -12 11 -26 7 8 -0 6 0 -6 -0
Profit After Tax 19 -18 42 3 28 -4 -6 -28 -0 -33
Adjustments -97 -16 -142 -8 -29 -6 -9 -9 89 1
Profit After Adjustments -77 -34 -100 -4 -1 -10 -14 -36 88 -32
Adjusted Earnings Per Share -4.5 -2 -5.8 -0.2 -0 -0.5 -0.8 -1.9 4.6 -1.7

Camlin Fine Sciences Profit & Loss

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Net Sales 489 534 721 892 1049 1187 1412 1682 1454 1629 1723 1862
Other Income 4 16 13 14 3 11 37 6 44 15 29 33
Total Income 494 550 734 906 1053 1198 1449 1688 1498 1644 1752 1894
Total Expenditure 398 503 706 819 914 1000 1258 1469 1313 1402 1606 1776
Operating Profit 96 46 28 87 139 198 191 219 185 242 146 119
Interest 24 31 32 41 48 48 41 66 70 107 83 74
Depreciation 17 22 27 29 33 44 56 63 56 61 71 76
Exceptional Income / Expenses -5 0 0 0 0 0 0 -10 0 -10 -25 -37
Profit Before Tax 50 -6 -31 17 58 105 94 80 59 65 -32 -69
Provision for Tax 14 -2 -7 14 28 40 34 41 6 -1 -0 0
Profit After Tax 36 -4 -24 3 30 65 60 40 53 65 -32 -67
Adjustments 0 -7 -6 -2 0 -14 0 12 -146 -204 59 72
Profit After Adjustments 36 -11 -30 1 30 51 61 52 -93 -139 28 6
Adjusted Earnings Per Share 3.6 -1.1 -2.4 0 2.4 3.9 3.8 3.2 -5.4 -7.4 1.4 0.2

Camlin Fine Sciences Balance Sheet

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Shareholder's Funds 176 213 371 371 403 643 748 819 865 902 1041
Minority's Interest 0 18 62 59 57 70 17 5 -8 -27 -40
Borrowings 21 51 110 194 212 273 388 408 333 268 303
Other Non-Current Liabilities -10 -19 -38 -39 -26 -15 16 5 -11 -31 -41
Total Current Liabilities 280 386 471 460 548 478 595 793 732 846 974
Total Liabilities 468 648 977 1046 1193 1449 1764 2030 1911 1959 2237
Fixed Assets 140 199 276 270 304 581 601 858 816 702 887
Other Non-Current Assets 28 30 35 103 215 72 269 85 94 74 113
Total Current Assets 300 419 666 672 675 795 891 1086 999 1183 1234
Total Assets 468 648 977 1046 1193 1449 1764 2030 1911 1959 2237

Camlin Fine Sciences Cash Flow

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Opening Cash & Cash Equivalents 9 8 21 38 53 52 76 108 94 80 104
Cash Flow from Operating Activities 72 -9 -15 -9 86 117 145 51 139 23 82
Cash Flow from Investing Activities -66 -83 -149 -2 -90 -133 -249 -125 -66 -75 -53
Cash Flow from Financing Activities -7 91 182 26 3 39 136 60 -86 76 -25
Net Cash Inflow / Outflow -1 -1 18 15 -1 23 32 -14 -13 24 4
Closing Cash & Cash Equivalent 8 21 38 53 52 76 108 94 80 104 109

Camlin Fine Sciences Ratios

# Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Earnings Per Share (Rs) 3.62 -1.05 -2.39 0.05 2.44 3.91 3.78 3.24 -5.41 -7.4 1.44
CEPS(Rs) 5.34 1.64 0.22 2.58 5.05 8.4 7.24 6.36 6.38 6.71 2.05
DPS(Rs) 0.44 0 0 0 0 0 0 0 0 0 0
Book NAV/Share(Rs) 17.81 19.87 28.1 28.08 32.44 37.68 40.65 46.1 47.01 47.23 53.37
Core EBITDA Margin(%) 18.2 5.61 2.03 8.17 12.89 15.73 10.92 12.63 9.68 13.9 6.78
EBIT Margin(%) 14.77 4.49 0.15 6.46 10.09 12.91 9.54 8.72 8.84 10.52 2.95
Pre Tax Margin(%) 9.92 -1.1 -4.25 1.87 5.55 8.85 6.66 4.78 4.03 3.97 -1.86
PAT Margin (%) 7.1 -0.81 -3.32 0.34 2.84 5.51 4.28 2.37 3.64 4 -1.83
Cash Profit Margin (%) 10.49 3.18 0.37 3.59 5.97 9.24 8.24 6.09 7.52 7.74 2.29
ROA(%) 8.13 -0.8 -2.95 0.3 2.66 4.95 3.76 2.1 2.69 3.36 -1.5
ROE(%) 23.04 -2.29 -8.57 0.86 7.94 14.61 10.55 5.71 6.85 7.69 -3.3
ROCE(%) 22.86 5.46 0.17 7.32 12.02 15.25 11.37 10.38 8.53 11.44 3.16
Receivable days 68.37 73.54 88.44 84.82 80.39 80.48 73.72 65.58 74.03 68.73 74.26
Inventory Days 112.09 123.85 110.3 107.28 101.51 95.03 89.29 101.91 135.67 116.49 109.14
Payable days 181.39 121.7 110.68 131.61 115.68 103.88 94.24 117.17 145.31 162.08 180.42
PER(x) 23.88 0 0 1047.27 15.76 34.97 36.09 38.39 0 0 67.41
Price/Book(x) 4.85 4.4 3.54 1.73 1.19 3.62 3.35 2.7 1.85 3.55 1.82
Dividend Yield(%) 0.51 0 0 0 0 0 0 0 0 0 0
EV/Net Sales(x) 2.08 2.3 2.16 1.08 0.89 1.84 1.89 1.59 1.42 2.22 1.38
EV/Core EBITDA(x) 10.59 26.47 56.61 11.1 6.77 11.05 13.99 12.25 11.13 14.97 16.32
Net Sales Growth(%) -12.35 9.11 34.96 23.81 17.6 13.15 18.95 19.08 -13.54 12.02 5.81
EBIT Growth(%) -2.87 -67.01 -95.62 6271.24 83.61 44.79 -12.05 8.79 -12.32 33.22 -70.27
PAT Growth(%) -34.92 -112.39 -440.01 112.45 892.44 119.1 -7.63 -34.06 33.03 22.9 -148.44
EPS Growth(%) -35.42 -129.08 -126.93 101.95 5152.94 59.86 -3.3 -14.19 -266.98 -36.75 119.44
Debt/Equity(x) 1.02 1.57 1.07 1.32 1.31 1.09 0.95 1.05 0.82 0.69 0.65
Current Ratio(x) 1.07 1.09 1.41 1.46 1.23 1.66 1.5 1.37 1.36 1.4 1.27
Quick Ratio(x) 0.45 0.57 0.91 0.84 0.69 0.99 0.87 0.65 0.66 0.78 0.75
Interest Cover(x) 3.05 0.8 0.03 1.41 2.22 3.18 3.3 2.21 1.84 1.61 0.61
Total Debt/Mcap(x) 0.21 0.36 0.3 0.76 1.1 0.3 0.28 0.39 0.44 0.2 0.36

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +6% +1% +8% +13%
Operating Profit CAGR -40% -13% -6% +4%
PAT CAGR -149% 0% 0% 0%
Share Price CAGR -50% -17% -12% -1%
ROE Average -3% +4% +6% +6%
ROCE Average +3% +8% +9% +10%

Camlin Fine Sciences Shareholding Pattern

Latest · Sep 2026
100% held
Promoters 48.03 %
FII 0.95 %
DII (MF + Insurance) 5.31 %
Public (retail) 45.71 %
# Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Promoter 48.0248.0248.0249.149.149.0848.0348.0348.0348.03
FII 1.010.810.761.472.882.122.120.940.910.95
DII 4.884.233.383.834.145.477.767.695.415.31
Public 46.0846.9347.8345.6143.8843.3342.0943.3345.6545.71
Others 0000000000
Total 100100100100100100100100100100

Camlin Fine Sciences Peer Comparison

Chemicals Edit Columns

Camlin Fine Sciences Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Camlin Fine Sciences Pros & Cons

Pros

Cons

  • Promoter holding is low: 48.03%.
  • Company has a low return on equity of 4% over the last 3 years.
  • Debtor days have increased from 162.08 to 180.42days.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp